Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

Sofetabart mipitecan received FDA breakthrough therapy designation for platinum-resistant ovarian cancer after prior ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its potential to improve treatment outcomes. The designation is based on phase 1 ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Eli Lilly and Co. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for a drug in ...

Oscar Murphy has an aggressive form of the blood cancer and is the first to get CAR-T therapy in the UK.

HHMI Investigator Kevan Shokat and his lab are charting new therapies to outmaneuver drug resistance and better target common cancer cell mutations.

Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...

Fox News senior medical analyst Dr. Marc Siegel joins ‘Fox & Friends’ to discuss a new study on breast cancer treatment and ...

Jorge Manchola, a retired Air Force staff sergeant, was diagnosed with stage 4 lung cancer in 2023. The cancer had spread to ...